vs
Side-by-side financial comparison of BXP, Inc. (BXP) and Medpace Holdings, Inc. (MEDP). Click either name above to swap in a different company.
BXP, Inc. is the larger business by last-quarter revenue ($872.1M vs $708.5M, roughly 1.2× Medpace Holdings, Inc.). Medpace Holdings, Inc. runs the higher net margin — 19.1% vs 15.3%, a 3.8% gap on every dollar of revenue. On growth, Medpace Holdings, Inc. posted the faster year-over-year revenue change (32.0% vs 0.8%). Over the past eight quarters, Medpace Holdings, Inc.'s revenue compounded faster (17.7% CAGR vs 1.3%).
BXP Inc., operating as Boston Properties, is a leading U.S. real estate investment trust focused on owning, managing and developing high-quality Class A commercial office properties across major U.S. metro markets, serving diverse corporate, tech and professional service tenants.
Medpace Holdings, Inc. is a global clinical research organization (CRO) based in Cincinnati, Ohio, employing approximately 6,000 people. Operating under a full-service model, the company also offers global central laboratory, imaging core laboratory, and bioanalytical laboratory services, as well as a Phase I unit located on its headquarters and clinical research campus in Cincinnati, Ohio.
BXP vs MEDP — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $872.1M | $708.5M |
| Net Profit | $133.0M | $135.1M |
| Gross Margin | — | — |
| Operating Margin | — | 21.6% |
| Net Margin | 15.3% | 19.1% |
| Revenue YoY | 0.8% | 32.0% |
| Net Profit YoY | 53.0% | 15.5% |
| EPS (diluted) | $1.69 | $4.65 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $872.1M | — | ||
| Q4 25 | $877.1M | $708.5M | ||
| Q3 25 | $871.5M | $659.9M | ||
| Q2 25 | $868.5M | $603.3M | ||
| Q1 25 | $865.2M | $558.6M | ||
| Q4 24 | $858.6M | $536.6M | ||
| Q3 24 | $859.2M | $533.3M | ||
| Q2 24 | $850.5M | $528.1M |
| Q1 26 | $133.0M | — | ||
| Q4 25 | $248.4M | $135.1M | ||
| Q3 25 | $-121.7M | $111.1M | ||
| Q2 25 | $89.0M | $90.3M | ||
| Q1 25 | $61.2M | $114.6M | ||
| Q4 24 | $-228.9M | $117.0M | ||
| Q3 24 | $83.6M | $96.4M | ||
| Q2 24 | $79.6M | $88.4M |
| Q1 26 | — | — | ||
| Q4 25 | 58.8% | — | ||
| Q3 25 | 59.3% | — | ||
| Q2 25 | 59.2% | — | ||
| Q1 25 | 59.2% | — | ||
| Q4 24 | 59.7% | — | ||
| Q3 24 | 59.5% | — | ||
| Q2 24 | 59.8% | — |
| Q1 26 | — | — | ||
| Q4 25 | — | 21.6% | ||
| Q3 25 | — | 21.5% | ||
| Q2 25 | — | 20.9% | ||
| Q1 25 | — | 20.3% | ||
| Q4 24 | — | 23.4% | ||
| Q3 24 | — | 21.1% | ||
| Q2 24 | — | 19.9% |
| Q1 26 | 15.3% | — | ||
| Q4 25 | 28.3% | 19.1% | ||
| Q3 25 | -14.0% | 16.8% | ||
| Q2 25 | 10.2% | 15.0% | ||
| Q1 25 | 7.1% | 20.5% | ||
| Q4 24 | -26.7% | 21.8% | ||
| Q3 24 | 9.7% | 18.1% | ||
| Q2 24 | 9.4% | 16.7% |
| Q1 26 | $1.69 | — | ||
| Q4 25 | $1.56 | $4.65 | ||
| Q3 25 | $-0.77 | $3.86 | ||
| Q2 25 | $0.56 | $3.10 | ||
| Q1 25 | $0.39 | $3.67 | ||
| Q4 24 | $-1.46 | $3.67 | ||
| Q3 24 | $0.53 | $3.01 | ||
| Q2 24 | $0.51 | $2.75 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $512.8M | $497.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $7.7B | $459.1M |
| Total Assets | $25.1B | $2.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $512.8M | — | ||
| Q4 25 | $1.5B | $497.0M | ||
| Q3 25 | $861.1M | $285.4M | ||
| Q2 25 | $447.0M | $46.3M | ||
| Q1 25 | $398.1M | $441.4M | ||
| Q4 24 | $1.3B | $669.4M | ||
| Q3 24 | $1.4B | $656.9M | ||
| Q2 24 | $685.4M | $510.9M |
| Q1 26 | $7.7B | — | ||
| Q4 25 | $5.1B | $459.1M | ||
| Q3 25 | $5.0B | $293.6M | ||
| Q2 25 | $5.3B | $172.4M | ||
| Q1 25 | $5.3B | $593.6M | ||
| Q4 24 | $5.4B | $825.5M | ||
| Q3 24 | $5.8B | $881.4M | ||
| Q2 24 | $5.8B | $763.6M |
| Q1 26 | $25.1B | — | ||
| Q4 25 | $26.2B | $2.0B | ||
| Q3 25 | $26.0B | $1.8B | ||
| Q2 25 | $25.6B | $1.6B | ||
| Q1 25 | $25.4B | $1.9B | ||
| Q4 24 | $26.1B | $2.1B | ||
| Q3 24 | $26.4B | $2.1B | ||
| Q2 24 | $25.5B | $1.9B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $192.7M |
| Free Cash FlowOCF − Capex | — | $188.1M |
| FCF MarginFCF / Revenue | — | 26.6% |
| Capex IntensityCapex / Revenue | 1.5% | 0.6% |
| Cash ConversionOCF / Net Profit | — | 1.43× |
| TTM Free Cash FlowTrailing 4 quarters | — | $681.9M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $407.8M | $192.7M | ||
| Q3 25 | $274.2M | $246.2M | ||
| Q2 25 | $353.1M | $148.5M | ||
| Q1 25 | $210.0M | $125.8M | ||
| Q4 24 | $383.7M | $190.7M | ||
| Q3 24 | $286.1M | $149.1M | ||
| Q2 24 | $367.1M | $116.4M |
| Q1 26 | — | — | ||
| Q4 25 | $362.7M | $188.1M | ||
| Q3 25 | $231.6M | $235.5M | ||
| Q2 25 | $281.5M | $142.4M | ||
| Q1 25 | $152.6M | $115.8M | ||
| Q4 24 | $312.5M | $183.0M | ||
| Q3 24 | $234.5M | $138.5M | ||
| Q2 24 | $332.4M | $103.5M |
| Q1 26 | — | — | ||
| Q4 25 | 41.4% | 26.6% | ||
| Q3 25 | 26.6% | 35.7% | ||
| Q2 25 | 32.4% | 23.6% | ||
| Q1 25 | 17.6% | 20.7% | ||
| Q4 24 | 36.4% | 34.1% | ||
| Q3 24 | 27.3% | 26.0% | ||
| Q2 24 | 39.1% | 19.6% |
| Q1 26 | 1.5% | — | ||
| Q4 25 | 5.1% | 0.6% | ||
| Q3 25 | 4.9% | 1.6% | ||
| Q2 25 | 8.2% | 1.0% | ||
| Q1 25 | 6.6% | 1.8% | ||
| Q4 24 | 8.3% | 1.4% | ||
| Q3 24 | 6.0% | 2.0% | ||
| Q2 24 | 4.1% | 2.4% |
| Q1 26 | — | — | ||
| Q4 25 | 1.64× | 1.43× | ||
| Q3 25 | — | 2.22× | ||
| Q2 25 | 3.97× | 1.65× | ||
| Q1 25 | 3.43× | 1.10× | ||
| Q4 24 | — | 1.63× | ||
| Q3 24 | 3.42× | 1.55× | ||
| Q2 24 | 4.61× | 1.32× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BXP
| Lease | $818.2M | 94% |
| Parking and other | $30.8M | 4% |
| Development and management services | $9.2M | 1% |
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
